$CLVS News
Last published 3y ago
- 3y agoCLVSClovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286Business WireReceives Commitment for up to $75 Million in Debtor-in-Possession Financing Clovis Oncology, Inc. (NASDAQ:CLVS) ("Clovis" or the Company"), a biopharmaceutical company focused on acquiring, developing, and
- 3y agoTSLAMSSBNYUAL+14Stocks making the biggest moves midday: Tesla, V.F. Corporation, Marriott, MGM and moreCNBCThese are the stocks posting the largest moves in midday trading.
- 4y agoCLVSCRDFMRKONCY+1Rising Incidence of Pancreatic Cancer Driving Demand for Advanced Treatment TherapiesPR NewswireFinancialNewsMedia.com News Commentary - PALM BEACH, Fla., Nov. 7, 2022 /PRNewswire/ -- While there is no cure for pancreatic cancer in the pancreatic cancer treatment market, new treatment options abound, and research
- 4y agoCLVSClovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific RetreatBusiness WireClovis Oncology, Inc. (NASDAQ:CLVS) today announced the presentation of data from the TRITON3 Phase 3 trial in men with metastatic castration-resistant prostate cancer with BRCA or ATM mutations. The presentation
- 4y agoCLVSClovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM CongressBusiness WireUpdated LuMIERE Phase 1 data demonstrated a manageable safety profile with some preliminary evidence of anti-tumor activity Eleven patients treated to date with 177Lu-FAP-2286 up to 7.4 GBq/dose No serious adverse
- 4y agoCLVSTRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM MutationsBusiness WireTRITON3 study evaluating Rubraca monotherapy versus chemotherapy or second-line androgen deprivation therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) with mutations in BRCA or ATM achieved the primary endpoint of improv
- 4y agoCLVSClovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply AgreementBusiness WireIsotopia to supply its medical radioisotope, lutetium-177, for the clinical development of Clovis Oncology's targeted radionuclide therapy candidate FAP-2286 Clovis Oncology, Inc. (NASDAQ:CLVS) and Isotopia Molecular Imaging Ltd. today announced the
- 4y agoCLVSClovis Oncology's Rubraca® (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk SubgroupsBusiness WireSubgroup analysis from the Phase 3 ATHENA trial evaluating Rubraca monotherapy versus placebo (ATHENA-MONO) presented in a Mini Oral session at the ESMO Congress 2022 Results reinforce potential of Rubraca as a first-line maintenance treatment opt
- 4y agoCLVSClovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development ProgramsBusiness WireFirst presentation of initial LuMIERE Phase 1 clinical data for FAP-2286 targeted radiotherapy candidate at SNMMI demonstrated a manageable safety profile with preliminary evidence of activity Confirmed partial response in one patient in the lowes
- 4y agoCLVSClovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8Business WireClovis Oncology, Inc. (NASDAQ:CLVS) will announce its second quarter 2022 financial results and provide an update on its clinical development programs and regulatory and business outlook on Monday, August 8, 2022, before the open of the US financial mar
- 4y agoCLVSNorthStar Medical Radioisotopes Announces Supply Agreement with Clovis Oncology for Therapeutic Radioisotope Actinium-225 (Ac-225)Business WireNorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the signing of a long-term supply agreement with
- 4y agoCLVSClovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual MeetingBusiness WireFirst presentation of initial LuMIERE Phase 1 data demonstrated a manageable safety profile with preliminary evidence of activity Nine patients treated to date with 177Lu-FAP-2286 up to 5.5 GBq/dose No serious adverse events, treatment discont
- 4y agoCLVSClovis Oncology's Rubraca® (Rucaparib) as First-Line Maintenance Treatment Significantly Improves Progression-Free Survival in Women with Advanced Ovarian Cancer in Primary Efficacy Analyses Regardless of BRCA Mutation and HRD StatusBusiness WireFirst presentation of data from the Phase 3 ATHENA trial evaluating Rubraca monotherapy versus placebo (ATHENA-MONO) to be presented as a late-breaking, oral abstract at the 2022 ASCO Annual Meeting and published simultaneously in the Journal of Clini
- 4y agoBBIGCLVSDBGIENDP+1Thinking about buying stock in Vinco Ventures, Digital Brands, Endo, Clovis Oncology, or Under Armour?PR NewswireNEW YORK, May 6, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BBIG, DBGI, ENDP, CLVS, and UAA. To
- 4y agoCLVSClovis Oncology to Present at the BofA Securities 2022 Healthcare ConferenceBusiness WireClovis Oncology, Inc. (NASDAQ:CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 10:00 a.m. Pacific time. The conference
- 4y agoBLTECLVSENDPONCY+1HER2-Targeted Therapies Introduced Early in Breast Cancer Treatment Offering Hope for PatientsPR NewswirePALM BEACH, Fla. , May 4, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Globally, the R&D on breast cancer in all its forms has been steadily growing at a significant pace over the last several years and will continue in the years to com
- 4y agoCLVSClovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development ProgramsBusiness WireATHENA study evaluating Rubraca® (rucaparib) monotherapy versus placebo (ATHENA-MONO) in first-line ovarian cancer maintenance treatment successfully achieved the primary endpoint of improved PFS in both populations in the primary efficacy analyses:
- 4y agoCLVSClovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual MeetingBusiness WireIncludes presentation of additional late-breaking Phase 3 ATHENA-MONO trial data as complement to previously announced topline data Clovis Oncology, Inc. (NASDAQ:CLVS), announced today that seven abstracts from the company's pipeline, including late-
- 4y agoBVAXFCLVSCTICIMGN+1Advanced Immunological and Clinical Trials for Treating Ovarian Cancer AcceleratingPR NewswirePALM BEACH, Fla., April 25, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer remains undetected until the mutation spre
- 4y agoCLVSClovis Oncology to Announce First Quarter 2022 Financial Results and Host Webcast Conference Call on May 4Business WireClovis Oncology, Inc. (NASDAQ:CLVS) will announce its first quarter 2022 financial results on Wednesday, May 4, 2022, before the open of the US financial markets. Clovis' senior management will host a conference call and live audio webcast at 8:30am ET
- 4y agoATRSCLVSGSKONCY+2Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases IncreasingPR NewswirePALM BEACH, Fla., April 14, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - CAR-T therapy is a sort of treatment in which a patient's T cells which is a type of immune system cell, are genetically modified to attack cancer cells in the lab.
- 4y agoCLVSClovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022Business WireAnalyses of non-clinical study data demonstrate longer tumor retention with 177Lu-FAP-2286 than 177Lu-FAPI-46, resulting in greater tumor inhibition Phase 1 data is expected later this year from the ongoing LuMIERE clinical trial evaluating FAP-22
- 4y agoARRYBTAICLVSCTXR+1Thinking about buying stock in Citius Pharmaceuticals, BioXcel Therapeutics, Array Technologies, Gogo, or Clovis Oncology?PR NewswireNEW YORK, April 6, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CTXR, BTAI, ARRY, GOGO, and CLVS.
- 4y agoCLVSClovis Oncology's Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3 ATHENA-MONO TrialBusiness WireATHENA study evaluating Rubraca monotherapy versus placebo (ATHENA-MONO) successfully achieved the primary endpoint of improved PFS in both populations in the primary efficacy analyses: HRD-positive and all patients randomized (ITT) Median PFS of
- 4y agoCLVSClovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-225-Labeled FAP-2286Business WireClovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of a development, manufacturing, and services agreement with Evergreen Theragnostics to develop actinium-225-labeled-FAP-2286 (225Ac-FAP-2286). Under the agreement, Clovis and Evergreen
- 4y agoBCELCLVSEOSEMARA+1Thinking about buying stock in Eos Energy Enterprises, Norwegian Cruise Line, Marathon Digital, Clovis Oncology, or Atreca?PR NewswireNEW YORK, March 9, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EOSE, NCLH, MARA, CLVS, and BCEL.
- 4y agoCLVSClovis Oncology Highlights Ongoing Phase 1/2 LuMIERE Clinical Study and Multi-Tumor Imaging Investigator-Initiated Trial of FAP-2286 Fibroblast Activation Protein-Targeted Radiotherapy Candidate at an Upcoming Nuclear Medicine MeetingBusiness WireClovis Oncology, Inc. (NASDAQ:CLVS) today announced a Trial-in-Progress poster detailing the Phase 1 portion of the LuMIERE clinical study for its targeted radiotherapy candidate FAP-2286 and a presentation titled "Initial Experience with FAP-2286 Imagi
- 4y agoCLVSClovis Oncology Announces 2021 Operating Results and Anticipated 2022 Development MilestonesBusiness WireThree top-line Phase 3 data read-outs for Rubraca expected in 2022, with potential to address larger ovarian and prostate cancer patient populations in earlier lines of therapy Phase 1/2 LuMIERE study of targeted radiotherapy candidate FAP-2286 on
- 4y agoCLVSClovis Oncology to Announce Fourth Quarter 2021 and Year End 2021 Financial Results and Host Webcast Conference CallBusiness WireClovis Oncology, Inc. (NASDAQ:CLVS) will announce its fourth quarter 2021 and year end 2021 financial results on Wednesday, February 23, 2022, before the open of the US financial markets. Clovis' senior management will host a conference call and live au
- 4y agoCLVSClovis Oncology Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021Business WireEstimated $35.5M - $36.1M in Rubraca® (rucaparib) global sales for Q4 2021 and $148.3M - $148.9M for FY 2021 Continuing impact on ovarian cancer diagnoses and treatments from COVID-19 Q4/FY 2021 Operating Results call planned for February 23,
- 4y agoCLVSClovis Oncology Highlights FAP-2286 Preclinical Data Presented at the Targeted Radiopharmaceuticals SummitBusiness WireClovis Oncology, Inc. (NASDAQ:CLVS) announced today's presentation by Andrew D. Simmons, Ph.D., Clovis' Senior Vice President, Translational Medicine, at the 3rd Targeted Radiopharmaceuticals Summit being held virtually December 7-9, 2021. Dr. Simmons'
- 5y agoARAYAZNCLVSMRK+1Global Metastatic Cancer Treatment Market Size Is Forecasted To Reach $111.16 Million By 2027PR NewswirePALM BEACH, Fla., Nov. 3, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The metastatic cancer treatment systems market is observing high demand attributed to its increasing application in breast, lung, melanoma, prostate, and colorectal
- 5y agoCLVSClovis Oncology Announces Third Quarter 2021 Operating ResultsBusiness Wire$37.9M in Rubraca® (rucaparib) global net product revenues for Q3 2021, up 3% over Q2 2021 and down 2% from Q3 2020 Three top-line Phase 3 data read-outs for Rubraca expected in 2022 with potential to address larger ovarian and prostate cancer pa
- 5y agoCLVSClovis Oncology to Announce Third Quarter 2021 Financial Results and Host Webcast Conference Call on November 3Business WireClovis Oncology, Inc. (NASDAQ:CLVS) will announce its third quarter 2021 financial results on Wednesday, November 3, 2021, before the open of the US financial markets. Clovis' senior management will host a conference call and live audio webcast at 8:30a
- 5y agoCLVSClovis Oncology and ITM Announce Lutetium-177 Clinical Supply AgreementBusiness WireITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Clovis Oncology's Targeted Radionuclide Therapy candidate FAP-2286 Clovis Oncology, Inc. (NASDAQ:CLVS) and ITM Isotope Technologies Munic
- 5y agoCLVSITM and Clovis Oncology Announce Lutetium-177 Clinical Supply AgreementBusiness WireITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Clovis Oncology's Targeted Radionuclide Therapy candidate FAP-2286 ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech compan
- 5y agoCLVSPan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286Business WireHigh expression of FAP, the target of radionuclide therapeutic development candidate FAP-2286, was observed across multiple tumor types and correlated with FAP-2286 binding Clovis Oncology's clinical development of FAP-2286 is underway with the Ph
- 5y agoCLVSCRVSIPHAONCY+1Global Radiotherapy Market Expected To Reach $7.3 Billion with a CAGR Of 4.2% By 2026PR NewswirePALM BEACH, Fla., Sept. 20, 2021 /PRNewswire/ -- Over the last decade, the radiotherapy devices market has seen significant technological advancements. These advancements have helped in the development of more effective, low-cost, and easy-to-use radio
- 5y agoCLVSClovis Oncology Retires Remaining 2021 Notes and Raises Additional Capital through its ATM Equity Offering ProgramBusiness WireThree Phase 3 topline Rubraca data readouts expected in 2022 Initial data from LuMIERE study of targeted radiotherapy candidate FAP-2286 also expected in 2022 Improved balance sheet complements ongoing focus on cost control Clovis Oncology, Inc
- 5y agoCLVSClovis Oncology Announces Renewal of At-The-Market Equity Offering ProgramBusiness WireClovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission ("SEC") to renew its previously established ATM facility under which it may offer and sell, from time to time,
- 5y agoCLVSClovis Oncology to Announce Second Quarter 2021 Financial Results and Host Webcast Conference Call on August 4Business WireClovis Oncology, Inc. (NASDAQ:CLVS) will announce its second quarter 2021 financial results on Wednesday, August 4, 2021, before the open of the US financial markets. Clovis' senior management will host a conference call and live audio webcast at 8:30am
- 5y agoAACIDMCLVSSKLZ+1Thinking about buying stock in Cinedigm, VEON, Alcoa, Clovis Oncology, or Skillz?PR NewswireNEW YORK, July 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CIDM, VEON, AA, CLVS, and SKLZ. To
- 5y agoAHTATOSCLVSWIT+1Thinking about buying stock in Ashford Hospitality Trust, Clovis Oncology, Exela Technologies, Wipro, or Atossa Therapeutics?PR NewswireNEW YORK, July 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AHT, CLVS, XELA, WIT, and ATOS. To
- 5y agoAVGRCLVSEDUERIC+1Thinking about buying stock in Nokia, Clovis Oncology, Avinger, Ericsson, or New Oriental Education?PR NewswireNEW YORK, July 13, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NOK, CLVS, AVGR, ERIC, and EDU. To
- 5y agoCLVSClovis Oncology Appoints Dr. Ronit Simantov to its Board of DirectorsBusiness WireClovis Oncology, Inc. (NASDAQ:CLVS) announced today the appointment of Dr. Ronit Simantov to its Board of Directors, effective today. "I am very pleased to welcome Dr. Ronit Simantov to the Clovis Oncology Board of Directors, as she brings a wealth o
- 5y agoASTSCLVSMTSLTBLT+1Thinking about buying stock in Toughbuilt Industries, MER Telemanagement Solutions, United Airlines, AST SpaceMobile, or Clovis Oncology?PR NewswireNEW YORK, July 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TBLT, MTSL, UAL, ASTS, and CLVS. T
- 5y agoAVXLBMYCLVSCNSPGlobal Glioblastoma Multiforme (GBM) Treatment Market Could Reach Nearly $1.8 Billion By 2027PR NewswirePALM BEACH, Fla., June 29, 2021 /PRNewswire/ -- Glioblastoma multiforme (GBM) is one of the areas where the research & development investments are high and where global studies are growing. Everyone is looking to solve the problem. GBM, a fast-growing
- 5y agoCLVSInitial Clinical Experience of FAP-2286 in Independent Named Patient Use Published in The Journal of Nuclear MedicineBusiness WireFAP-2286 is an investigational targeted radionuclide therapeutic and imaging agent targeting fibroblast activation protein (FAP) Clovis Oncology initiated sponsored clinical development of FAP-2286 with the Phase 1/2 LuMIERE clinical trial in pati
- 5y agoCLVSA Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE) - NCT04939610ClinicalTrials.govDetermine the recommended Phase 2 dose of 177Lu-FAP-2286 (Phase 1), Objective response rate (ORR) (Phase 2), Radiation dosimetry of 177Lu-FAP-2286 (Phase 1), (and 9 more...)
- 5y agoCLVSClovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for EnrollmentBusiness WireFirst clinical site for Phase 1/2 LuMIERE clinical study of novel peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein (FAP) now open for enrollment FAP-2286 is the first peptide-targeted radionuclide th